ACAD - ACADIA PHARMACEUTICALS INC

QQQ $ 615.50 $ -6.29 (-1.01 %)

DIA $ 470.35 $ -1.68 (-0.36 %)

SPY $ 672.95 $ -3.55 (-0.52 %)

TLT $ 89.68 $ 0.12 (0.13 %)

GLD $ 367.13 $ -0.06 (-0.02 %)

Previous Close

$ 22.33

Open

$ 23.18

Bid

$ 21.50 x 400

Ask

$ 21.53 x 110

Day's Range

$ 20.98 - $ 23.18

52 Week Range

$ 13.40 - $ 26.65

Volume

2,342,153

Average Volume

Market Cap

3.78B

Beta (5Y Monthly)

$ 0.75

PE Ratio (TTM)

$ 14.46

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	11-05-2025	09-30-2025	10-Q
2	08-06-2025	06-30-2025	10-Q
3	05-08-2025	03-31-2025	10-Q
4	02-27-2025	12-31-2024	10-K
5	11-06-2024	09-30-2024	10-Q
6	08-06-2024	06-30-2024	10-Q
7	05-08-2024	03-31-2024	10-Q
8	02-28-2024	12-31-2023	10-K
9	11-02-2023	09-30-2023	10-Q
10	08-02-2023	06-30-2023	10-Q
11	05-08-2023	03-31-2023	10-Q
12	02-28-2023	12-31-2022	10-K
13	11-03-2022	09-30-2022	10-Q
14	08-08-2022	06-30-2022	10-Q
15	05-04-2022	03-31-2022	10-Q
16	03-01-2022	12-31-2021	10-K
17	11-08-2021	09-30-2021	10-Q
18	08-04-2021	06-30-2021	10-Q
19	05-06-2021	03-31-2021	10-Q
20	02-25-2021	12-31-2020	10-K
21	11-04-2020	09-30-2020	10-Q
22	08-06-2020	06-30-2020	10-Q
23	05-08-2020	03-31-2020	10-Q
24	02-27-2020	12-31-2019	10-K
25	10-31-2019	09-30-2019	10-Q
26	08-01-2019	06-30-2019	10-Q
27	05-02-2019	03-31-2019	10-Q
28	02-27-2019	12-31-2018	10-K
29	11-06-2018	09-30-2018	10-Q
30	08-08-2018	06-30-2018	10-Q
31	05-04-2018	03-31-2018	10-Q
32	02-27-2018	12-31-2017	10-K
33	11-07-2017	09-30-2017	10-Q
34	08-08-2017	06-30-2017	10-Q
35	05-09-2017	03-31-2017	10-Q
36	02-28-2017	12-31-2016	10-K
37	11-07-2016	09-30-2016	10-Q
38	08-04-2016	06-30-2016	10-Q
39	05-05-2016	03-31-2016	10-Q
40	02-29-2016	12-31-2015	10-K

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

RBC Capital Maintains Outperform on ACADIA...
11/06/2025 15:35:13

RBC Capital analyst Brian Abrahams maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Outperform and lowers the price tar...

Beyond The Numbers: 6 Analysts Discuss ACA...
11/06/2025 11:45:35

Needham Maintains Buy on ACADIA Pharmaceut...
11/06/2025 10:07:05

Needham analyst Ami Fadia maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and raises the price target from $28 to ...

CORRECTION: ACADIA Pharmaceuticals Q3 Adj....
11/05/2025 22:54:03

ACADIA Pharmaceuticals (NASDAQ:ACAD) reported quarterly earnings of $0.26 per share which beat the analyst consensus estimate o...

ACADIA Pharmaceuticals Raises FY2025 Sales...
11/05/2025 21:44:37

Full Year 2025 Financial GuidanceTotal Revenues in the range of $1.070 to $1.095 billion, compared with the prior guidance rang...

ACADIA Pharmaceuticals Q3 EPS $0.42 May No...
11/05/2025 21:43:08

Earnings Scheduled For November 5, 2025
11/05/2025 11:12:12

ACADIA Pharmaceuticals's Earnings: A Preview
11/04/2025 18:01:37

this-acadia-pharmaceuticals-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-tuesday

This ACADIA Pharmaceuticals Analyst Begins...
10/21/2025 12:35:30

Citigroup Initiates Coverage On ACADIA Pha...
10/21/2025 10:51:16

Citigroup analyst Yigal Nochomovitz initiates coverage on ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy rating and announc...

Acadia Pharmaceuticals To Present ACP-711 ...
10/02/2025 13:06:46

Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced one late-breaker oral platform presentation and two poster presentati...

Beyond The Numbers: 11 Analysts Discuss AC...
09/29/2025 14:03:05

In the preceding three months, 11 analysts have released ratings for ACADIA Pharmaceuticals (NASDAQ: ACAD), presenting a wide a...

JP Morgan Maintains Overweight on ACADIA P...
09/29/2025 12:10:00

JP Morgan analyst Tessa Romero maintains ACADIA Pharmaceuticals (NASDAQ: ACAD) with a Overweight and lowers the price target...

Needham Maintains Buy on ACADIA Pharmaceut...
09/24/2025 14:54:06

Needham analyst Ami Fadia maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and lowers the price target from $30 to ...

acadia-pharma-faces-trial-setback-as-prader-willi-syndrome-trial-falls-short

Acadia Pharma Faces Trial Setback As Prade...
09/24/2025 14:05:05

Acadia's Phase 3 Compass Prader-Willi syndrome trial failed to meet endpoints, but the company projects $1 billion in sales...

12 Health Care Stocks Moving In Wednesday'...
09/24/2025 12:10:28

Trading Halt: Halt status updated at 7:25:...
09/24/2025 11:25:04

Acadia's Phase 3 COMPASS PWS Trial Of Intr...
09/24/2025 11:02:53

Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced top-line results from the Phase 3 COMPASS PWS trial evaluating the ef...

Trading Halt: Halted at 6:55:13 a.m. ET - ...
09/24/2025 10:55:17

Acadia Pharma Announces Publication Of Int...
09/12/2025 20:07:49

-- Findings reinforce efficacy and tolerability profile in patients prescribed DAYBUE in the U.S. for as long as 12 months, con...